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Summary The toxicity due to interleukin-2 (IL-2) strongly resembles the clinical picture seen during septic
shock. In septic shock activation of polymorphonuclear neutrophils (PMN) and the complement system
contribute significantly to the pathophysiology of the condition. We therefore investigated whether similar
events contributed to the toxicity observed with IL-2.
Four patients received seven cycles of escalating dose IL-2 (18.0 to 72.0 x 106 IU m-2 day-') and 16 were
treated with 20 cycles of fixed dose IL-2 (12.0 or 18.0 x 106 IU m-2 day-'). Toxicity, as judged by hypotension
(P = <0.005) and capillary leakage (fall in serum albumin 18.2 vs 4.0 gm 1'; P = <0.0005 and weight gain
4.0 vs 1.2 kg; P = <0.025) were worse with the esc. dose protocol.
PMN became activated following IL-2 with mean peak elastase/a,-antitrypsin (Ea,A) and lactoferrin values
of 212 (SEM = 37) and 534 (SEM = 92) ng ml-' respectively occurring 6 h after the IL-2. Peak values for the
esc. dose IL-2 group being generally higher than 500 ng ml-'. Activation of the complement cascade was
evidenced by a dose dependent elevation of peak C3a values (fixed dose 9.1 (SEM = 0.6); esc. dose 25.7
(SEM = 6.33); P = <0.005) on day 5 of IL-2.
There was a significnt correlation between C3a levels and the degree of hypotention during the first 24 h
after IL-2 (r = 0.91) and parameters of capillary leakage such as weight gain and fall in serum albumin
(r = 0.71).
These data suggest that activation of PMN initiates endothelial cell damage which subsequently leads to
activation of the complement cascade. This latter system then contributes to the haemodynamic changes and
capillary leakage seen in IL-2 treated patients.
Interleukin-2 (IL-2) used either alone or given in combina-
tion with the adoptive transfer of in vitro generated lym-
phokine activated killer (LAK) cells is capable of inducing
durable remissions in 25 to 30% of patients with metastatic
malignant melanoma or renal carcinoma (Rosenberg et al.,
1989; Eberlein et al., 1988; West, 1989; Dutcher et al., 1989;
Fisher et al., 1989; Oliver, 1988). However, this therapy,
when given in high dosages is associated with many side
effects. Within hours of bolus administration the patients
develop hypotension which may require treatment with
vasoactive substances such as dopamine or norepinephrine.
After several days of IL-2 hypoalbuminemia, oedema and
weight gain are indications that capillary endothelial cells
have become damaged resulting in a capillary leak syndrome
(CLS) (Cotran et al., 1988). In severe cases capillary leakage
may result in ascites, pleural effusions or interstitial pul-
monary oedema, the latter being an occasional reason for
artificial ventilation. The pathophysiological changes induced
by IL-2 are very similar to those seen in patients in the early
phases of septic shock (Ognibene et al., 1988; Lee et al.,
1989; Gaynor et al., 1988).
Although the pathophysiology of septic shock is not com-
pletely understood, considerable evidence has been
accumulated to indicate that increased vascular permeability
in combination with vasodilatation are central events in its
development (Parker et al., 1983; Harris et al., 1987; McCabe
et al., 1983). Endothelial cell activation/damage are thought
to be mediated via the in vivo generation of cytokines such as
Interleukin-I (IL-1), Interferon-' (IFN-y) and tumour necro-
sis factor (TNF) (Harris et al., 1987). Vasodilatation has
been attributed to activation of the complement cascade and
the contact (intrinsic) coagulation system with subsequent
release of anaphylatoxins such as C3a, C5a, and bradykinin
(Bengtson & Heideman, 1988; Slotman et al., 1986; Nuijens
et al., 1988). In vitro endothelial cells have been shown to
produce chemotactic cytokines such as Interleukin-8 (IL-8)
and granulocyte-macrophage colony stimulating factor (GM-
CSF) upon stimulation with IL-1 or TNF (Matsushima et
al., 1989; Balkwill & Burke, 1989). These latter two cytokines
also induce the expression of adhesion molecules on the
surfaces of endothelial cells which will result in adherence of
PMN to the endothelium (Cotran & Pober, 1989; Ward &
Marks, 1989; Mantovani & Dejana, 1989; Di Giovani &
Duff, 1990). These adherent PMN, when activated by a
variety of agonists including C5a, and platelet activating
factor, may mediate blood vessel wall injury by the produc-
tion of lyososomal proteases and toxic oxygen radicals
(Stevens et al., 1986; Tonnesen et al., 1984; Jacobs et al.,
1980; Perez et al., 1983).
The similarity between septic shock and IL-2 toxicity have
lead us to explore whether the same pathological processes
may be operative in the two situations. Recently, we have
reported that both the complement cascade (Thijs et al.,
1990) and the contact system of coagulation (Hack et al.,
1991) are activated in patients receiving high dose IL-2. In
this paper we present data which indicate that the PMN may
play a central role in the generation of IL-2 related toxicity.
Patients and methods
Patients
Two groups of patients with metastatic malignant melanoma
or renal cell carcinoma undergoing IL-2 therapy in the
department of medical oncology were studied. All patients
gave informed consent and the protocols were approved by
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the ethical and scientific committees of the Free University
Hospital.
The first group of four previously untreated patients (one
female and three males; Median age 46 years; Performance
status 90 or 100%; three melanoma and one renal cell car-
cinoma) were admitted to the intensive care ward and
received escalating doses of IL-2 over a 12 day period. The
IL-2 dose was inceased every 3 days from a starting dose of
18.0 x 106 IU m-2 day- given as a 30 min infusion until the
maximum tolerated dose was reached. None of the patients
received more than 72.0 x 106 IU m-2 day-' of IL-2. All the
patients received Indomethacin 50 mg x 3/day and
acetaminophen 500 mg x 4/day. Frusemide was administered
in all patients when peripheral oedema developed and when
the blood pressure was adequate. Hypotension was treated
initially with plasma expanders and with dopamine or
norepinephrine if necessary.
The second group consisted of 16 patients (11 males and
five females; median age 54 years; performance status
80-100%; 11 renal cell carcinoma and five melanoma) who
were part of phase I or II studies of a combination of IFN-y
and IL-2. The IFN-y was given by intramuscular injection at
a dose of 100 11gm m-2 day-' for 5 consecutive days followed
by 5 days of IL-2 at a dose of either 12.0 or
18.0 x 106 IU m-2 day-' as a 15 min infusion. The treatment
was given in the medium care section of the medical
oncology ward. All patients received indomethacin and
paracetamol in the dosages stated above and no patient
required specific therapy for hypotension.
Drugs
The IFN-y was provided free of charge by Boehringer
Ingelheim BV, Alkmaar, The Netherlands and the IL-2 was
in part supplied free of charge by EuroCetus BV, Amster-
dam, The Netherlands.
Blood sampling
All blood samples were collected in 5 ml tubes that contained
EDTA and polybrene (10 mm and 0.05% (w/v), final concen-
trations respectively) to prevent activation of the complement
and contact coagulation systems (Nuijens et al., 1987). The
first group of patients had blood drawn before therapy and
then every 4 to 8 h during the IL-2 administration. In the
second group blood samples were taken before and at 1, 2, 3,
4, 6, 8, 10, 12 and 24 h after the start of IL-2 and then prior
to each daily infusion and 4 h afterwards. All samples were
stored at - 70°C until they were tested.
Measurements ofelastase/lcl-antitrypsin (Ec,A), lactoferrin
and C3a
Plasma levels of neutrophilic elastase were measured with an
assay that detects complexes between elastase and its
inhibitor, ol-antitrypsin. Samples to be tested were incubated
with polyclonal rabbit antibodies raised against purified
human neutrophilic elastase, that were coupled to CNBr-
activated sepharose (Pharmacia Fine Chemicals AB, Upp-
salla, Sweden), for 4 h at room temperature. Complexes
bound to the sepharose beads were then quantitated by a
subsequent incubation with a radiolabelled monoclonal
antibody against complexed human al-antitrypsin. Results
were related to a standard that consisted of pooled human
plasma to which purified elastase (1Ojig ml-') was added,
and were expressed as ng of elastase per ml. Lactoferrin was
measured with a sandwich-type radio-immuno assay and
results expressed as ng ml-l. Details of these assays will be
published separately (Nuijens et al., 1991). C3a levels were
assessed by a radio-immuno assay and expressed as nmol 1-'
(Hack et al., 1988). The intra- and inter-assay coefficients of
variation of these assays are <9.4%. Recoveries of purified
standards added to fresh plasma were 90 to 95%. The lower
limit of sensitivity of the C3a assay is 0.66 nmol 1- whereas
those for Ea,A and lactoferrin are 40 mg ml-'. The normal
values for EaxA, lactoferrin and C3a are < 100 ngml,
<400 ng ml-' and <5 nmol 1'-l respectively.
Statistical analysis
Differences in levels before and after the start of IL-2 were
analysed with a paired Student t-test. P values of less than
0.05 were considered to represent significant differences. The
correlation between parameters was assessed by linear regres-
sion analysis. Unless otherwise stated mean values are quoted
together with the standard error of the mean (SEM).
Results
Patients
The first group of four patients who received seven cycles of
escalating doses of IL-2 were managed in the intensive care
unit and all patients required supportive care with vasopres-
sors in order to maintain an adequate blood pressure (BP).
Further details of the haemodynamic changes observed in
these patients are provided in Table I and elsewhere (Thijs et
al., 1990).
The second group of 16 patients together received 20 cycles
of IL-2 in fixed daily dosage as described above. These
patients were nursed in the medium care section of the
oncology ward and none of them required admission to the
intensive care unit or vasopressor support for hypotention.
Details of the changes occurring in these patients during IL-2
therapy are listed in Table II.
Toxicity due to IL-2
All patients developed the typical side effects of IL-2 therapy
which have been well described previously. Briefly, acute
toxicity consisted of pyrexia, rigors, tachycardia and
hypotension. Chronic toxicity was manifested by a CLS char-
Table I Changes observed in four patients receiving seven cycles of
IL-2 over a 12-day period
Zenith or Time
Parameter Baseline nadir (hours) P value
Temperature 36.8 ± 0.3 38.8 ± 0.7 6 to 8 .0.0005
(QC)
Systolic BP 116 11 89 11 8 .0.0005
(mmHg)
Diastolic BP 67 ± 8 47 ± 8 8 .0.0005
(mmHg)
Heart rate 90±9 110±18 8 .0.0005
(beats min-'1)
Weight (kg) 71.3 ± 13.4 75.3 ± 12.8 Day 11 .0.005
Albumin 40 7 21.8 3.5 Day 11 .0.025
(gm ')
The IL-2 dose was escalated until the maximum tolerable dose was
reached. Values are given as the mean ± the standard deviation.
Table II Changes observed in 16 patients receiving 20 cycles of
fixed dose IL-2 daily for 5 consecutive days
Zenith or Time
Parameter Baseline nadir (hours) P value
Temperature 35.8 ± 0.7 38.8 ± 0.7 6 <0.0005
(OC)
Systolic BP 126±14 100±14 12 0.005<P .0.01
(mmHg)
Diastolic BP 78 9 61 6 12 0. <P .0.025
(mmHg)
Heart rate 81 13 106±11 6 .0.0005
(beats min ')
Weight (kg) 73.8 8.0 75.0 9.1 Day 5 .0.01
Albumin 34±4 30±4 Day 5 <0.0005
(gin -')
Values are given as the mean ± the standard deviation.98 J.W. BAARS et al.
acterised by weight gain, oedema and hypoalbuminemia
which increased progressively during the IL-2 therapy. Des-
pite the presence of oedema and the hypotention there was
no clinical evidence of cardiac failure as judged by a lack of
dyspnoea and normal central venous pressure and chest X-
rays. None of these patients required ventilatory support
during therapy. All toxicity was rapidly reversible upon ces-
sation of the IL-2.
The patients receiving escalating doses of IL-2 exerienced
more toxicity than the group given lower fixed daily dosages.
The acute haemodynamic side effects were more severe with
diastolic BP falling to a significantly lower level (P = £0.005)
and all the patients needing vasopressor support.
Haemodynamic monitoring showed a marked fall in
peripheral vascular resistance and a rise in cardiac output.
These data have been reported more fully in a previous paper
(Thijs et al., 1990). The CLS was also more severe as
adjudged by greater weight gain (4.0 vs 1.2 kg; P = <0.025)
and more signficant falls in serum albumin values (18.2 vs
4.0 gm I-'; P = 0.0005).
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EJC,A and lactoferrin values
Figure 1 shows the changes which occurred in the EcxA and
lactoferrin levels over the 24 h following the first IL-2
administration in the patients receiving fixed dose IL-2. The
mean baseline values of EaxA and lactoferrin were 61
(SEM = 8.3) and 197 (SEM = 43), respectively. The levels
became significantly elevated by 4 h (P = <0.005) and
reached peak values of 212 (SEM = 37) and 534 (SEM = 92)
ng ml-' respectively at 6 h after the IL-2. Following this they
fell progressively such that by 24 h they were not significantly
different from pre-treatment values (P = >0.05). Over the
full 5 days of therapy the daily rise in Ex,A and lactoferrin
following IL-2 remained similar. In comparison patients
receiving escalating doses of IL-2 generally had higher peak
values of EajA (>500 ng ml-) although the pattern of its
production was similar to the fixed daily dose group (data
not shown). Peripheral blood neutrophil counts were not
significantly different between days 1 and 5 of the IL-2 in
both groups of patients.
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Figure 2 a, Changes in the mean plasma C3a levels and mean
systolic blood pressure in 16 patients given either 12.0 or
18.0 x 106 IU m-2 of Interleukin-2. The systolic blood pressure is
plotted as the reciprocal of the absolute value in mmHg. b,
scatter-gram of the mean systolic blood pressures (mmHg) vs the
mean plasma C3a levels (nmol- 1'). , Plasma C3a levels;
- -, Reciprocal of the cystolic BP.
Activation ofthe complement cascade
Activation of the complement system, as assessed by changes
in the C3a component, in patients receiving fixed dose IL-2 is
illustrated in Figures 2 and 3. C3a levels became significantly
elevated by 5 to 6 h after IL-2 and reached a peak at 12 h.
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Figure 1 Changes in the plasma levels of the elastase/ax-
antitrypsin complex and lactoferrin in the first 24 h after a 15 min
infusion ofeither 12.0 or 18.0 x 101 IU m-' of Interleukin-2 in 16
patients with either melanoma or renal cell carcinoma.
- O-, Elastase; -, Lactoferrin.
The levels fell slightly between 12 and 24 h but remained
significantly elevated (P <0.05) compared to pre-treatment
values prior to the next IL-2 dose. Over the 5 day treatment
period there was a progressive rise in C3a levels from mean
day 1 values of 4.3 (SEM = 0.4) to 9.1 (SEM = 0.6) nmol 1'
on day 5 (day 1 vs day 5; P = <0.0005). Figure 3 also
demonstrates that the pattern of C3a elevation was similar
for patients receiving escalating doses of IL-2, but that the
levels reached significantly higher values by day 3 of treat-
ment compared to the fixed dose group (P = <0.05).
Correlation between activation ofthe complement system and
ofPMN and the CLS
Figure 2 shows the plasma C3a levels during the 24 h after
first IL-2 injection together with a plot of the reciprocol of
the mean systolic BP. There is a highly significant correlation
between the systolic BP and the degree of activation of the
complement system (r = 0.91; inset in Figure 2).
We have previously demonstrated that there is a strong
positive correlation between activation of the complement
cascade and the CLS in patients receiving escalating doses of
IL-2 up to the maximum tolerable dose (Thijs et al., 1990).
These observations are confirmed by the continuing
significance of the correlation between C3a values and serum
albumin when patients receiving both low and high dose IL-2
are included in the analysis (Figure 3; r = 0.71). There was
no correlation between levels of the activation products of
PMN (Ea,A and lactoferrin) and any parameter of the CLS.
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Figure 3 a, Changes in the C3a complement levels in patients
receiving either a daily fixed dose (12.0 or 18.0 x 106IU m2
day-') of IL-2 or daily IL-2 with doses being escalated from 18.0
to 72.0 x 106 IUm-2day-'. The bars represent the standard
deviations of the mean values. b, scatter-gram of the mean serum
albumin values (g -') vs the mean plasma C3a values (nmol I').
, Fixed doses IL-2 -0 , Escalating dose IL-2.
Discussion
In this study we have observed that the systemic administra-
tion of IL-2 to cancer patients induces a rise in the plasma
levels of Ex,A and lactoferrin which is indicative of the
activation of PMN in these patients. This activation was
maximal between 4 and 6 h after the bolus administration of
IL-2 (Figure 1). The activation of PMN preceded the induc-
tion of complement system activation with C3a levels
reaching a peak at 8 and 12 h after IL-2 injection (Figure 2).
With repeated IL-2 treatments complement system activity
increased progressively (Figure 3) whilst PMN activation
returned to normal within 24 h and peak activation did not
increase with continued IL-2 administration.
Both the acute haemodynamic toxicity of IL-2 and the
more chronic and cumulative toxicity manifested by the CLS
become more severe with increasing doses of IL-2 (Tables I
and II). The degree of PMN and complement activation, as
measured by plasma levels of Ea,A and C3a, are also highly
correlated with the dose of IL-2 administered (results section
and Figure 3). There is a very strong correlation between the
degree of hypotension and CLS induced by IL-2 and plasma
C3a levels (Figures 2 and 3). These data suggest that activa-
tion of the complement cascade are likely to be involved in
the development of IL-2 related toxicity.
Activated PMN are well recognised for their ability to
injure endothelial cells in vitro (Ward & Marks, 1989;
Oppenheim, 1983). Indeed in patients with septic shock, a
situation which strongly resembles the clinical picture after
IL-2 administration, PMN are believed to mediate vascular
damage (Parker & Parrillo, 1983; Bengtson, 1988; Slotman et
al., 1986; Tonnesen et al., 1984; Jacobs et al., 1980).
Activated PMN express increased amounts of adhesion
molecules (Ward & Marks, 1989) and become marginated by
adherence to vascular endothelium. The local production of
proteases, such as elastase, and highly toxic oxygen species
could then initiate endothelial cell activation/damage. In
vitro, PMN can be activated by several agonists including
cytokines such as TNF, GM-CSF and IL-8 as well as activa-
tion products of the complement system and in particular
C5a (Slotman et al., 1986; Matsushima et al., 1989; Balkwill
& Burke, 1989; Mantovani & Dejani, 1989; Tonnesen et al.,
1984; Jacobs et al., 1980). These cytokines have been shown
to be generated in vivo following IL-2 administration (Ward
& Marks, 1989; Chong et al., 1989; Gemlo et al., 1988; Mier
et al., 1988; Oppenheim, 1983). A recently published study by
Mier and colleagues (Mier et al., 1990) showed that peak
TNF levels occurred 2 h after IL-2 administration. Thus the
time course of the TNF generation in IL-2 treated patients
would be consistent with the hypothesis that it was the cause
of the PMN activation observed in this study. It appears that
the hypotension caused by the in vivo administration of TNF
is probably mediated by the release of toxic oxygen radicals
from activated PMN because the radical scavenger, superox-
ide dismutase, is able to ameliorate this toxicity (Hauser et
al., 1990). The role of TNF is further implied by the ability
of passive iummunisation against this cytokine to partially
abrogate IL-2 induced toxicity (Fraker et al., 1989). In the
study by Mier et al. (1990) the concurrent administration of
dexamethasone with IL-2 prevented the in vivo generation of
TNF. This resulted in an amelioration of the observed IL-2
induced perturbation of PMN function and a reduction in
the degree of hypotension and organ toxicity. These data
support the hypothesis that TNF is an important mediator of
IL-2 induced toxicity and that the initial damage to
endothelial cells results from TNF induced activation of
PMN.
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Figure 4 A schematic representation of the interactions between
IL-2 activated T lymphocytes, granulocytes and endothelial cells
which ultimately results in damage of the latter cells and thus the
capillary leak syndrome. (IL-2 = Interleukin-1; IL-6 = Inter-
leukin-6; IL-8 = Interleukin-8; GM-CSF = Granulocyte-
macrophage colony stimulating factor; G-CSF = Granulocyte
colony stimulating factor; TNF-P = Tumour necrosis factor-P;
IFN-y = Interferon-y; IFN-a & p = Interferons a & P).100 J.W. BAARS et al.
The initial activation of PMN, which started at 3 h after
the IL-2 infusion (see Figure 1), apparently was not due to
complement activation products since levels of C3a did not
increase until 6 h after the IL-2 (see Figure 2). As explained
above we assume that cytokines such as TNF-mediated the
initial activation of PMN. At 6 to 12 h, however, both Ea,A
as well as lactoferrin were still increased and at this time C3a
was also elevated (see Figure 2). Presumably, therefore, com-
plement activation had contributed to the later stages of the
PMN activation induced by IL-2. C5a rather than C3a
interacts with PMN (Jacobs et al., 1980). Because of this
interaction, C5a is very rapidly cleared from the circulation.
For this reason we did not measure C5a in these patients. We
assumed that the amount of C3a in plasma reflected the
amount of C5a generated.
The activation ofPMN and the production of proteases by
them, occurred only transiently following the bolus injection
of IL-2 (Figure 1). The activation of the complement cascade
increased progressively during IL-2 administration (Figure 3)
and this activation was highly correlated with the observed
fall in systolic BP (Figure 2) and the progressive development
of the CLS, as measured by the fall in serum albumin (Figure
3) or weight gain (Thijs et al., 1990). Several neutrophilic
proteases have been shown to cleave complement in vitro
(Perez et al., 1983). The in vivo production of these proteases,
as has been demonstrated to occur in this study, may well at
least in part be responsible for the complement activation
observed. Some of the cytokines generated in vivo upon IL-2
administration are known to affect the production of acute
phase proteins by the liver. One of these, C-reactive protein,
has been shown to be increased in IL-2 treated patients (Mier
et al., 1990), and via an interaction with lymphocytes can
lead to activation of the complement cascade. Once initiated
activation of the complement system leads to the generation
of other moieties which could further contribute to haemo-
dynamic toxicity (C3a and C5a are anaphylotoxins) and to
the exacerbation of endothelial cell membrane damage via
generation of the so called 'membrane attack complex'.
We have shown that PMN become activated during IL-2
therapy and that this activation may initiate a chain ofevents
which results in at least some of the toxicity observed in
these patients. It is likely that endothelial damage and the
CLS are multifactorial in origin with adherent lymphokine
activated killer and natural killer cells together with wide-
spread activation of endothelial cells by other cytokines also
playing a role (Slow et al., 1988; Aronson et al., 1988; Damle
& Doyle, 1989). Our study demonstrates that activation of
PMN and of the complement system contribute substantially
to these processes and may be one of the initiating events. A
schematic description of the events which we believe are
occurring following IL-2 administration, and which result in
endothelial damage and thus the CLS, are shown in Figure 4.
An understanding of the interrelationships between the
events which result in the haemodynamic changes and CLS
consequent upon IL-2 administration make it possible to
devise ways in which its toxicity can be ameliorated. For
example the use of superoxide dismutase may reduce the
endothelial cell damage caused by toxic oxygen species and
suppression of complement activation with C-1 inhibitor
might attenuate toxicity caused by activation products of this
system. It is our hope that interventions such as these will
provide the possibility of improving the quality of life for
patients receiving IL-2 based therapies.
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